Roxadustat for treatment of anemia in a cancer patient with endstage renal disease:A case report

BACKGROUNDMost cancer patients are accompanied by anemia, which will be more seriouswhen combined with end-stage renal disease (ESRD). At present, cancer-relatedanemia and renal anemia treatments mainly include erythropoiesis-stimulatingagents (ESAs), iron supplementation, and blood transfusion, but their effects areoften poor with several safety concerns. We have used roxadustat to treat anemiain a cancer patient with ESRD and achieved a successful outcome for the firsttime.CASE SUMMARYA 64-year-old man was diagnosed with right renal cancer (clear cell renal cellcarcinoma). He did not receive surgery or radiotherapy before admission. He wastreated with oral soltan (sunitinib malate) on April 18, 2017. During oral chemotherapy,he had numerous complications, including anemia, hypertension,thyroid hypofunction, skin pigment loss, and renal function deterioration. At last,he progressed to ESRD and began hemodialysis treatment. We initially treated thepatient with high-dose ESAs, iron supplementation, adequate dialysis, and evenblood transfusion, but his anemia did not improve. Roxadustat is a newlydeveloped drug for renal anemia treatment, but not for cancer-related anemia, letalone to treat anemia in cancer patients with ESRD. We prescribed oral roxadustatto the patient. After a period, his hemoglobin gradually increased. He did nothave obvious discomfort symptoms, and his tumor did not progress significantly.CONCLUSIONOral roxadustat could achieve good results in treating anemia in cancer patients with ESRD.

Multiplexed Detection of Fe^(3+), Cobalamin and Folate Using Fluorescent Nanoprobe-Based Microarrays and a Smartphone

This work reports on a smartphone-based quantitative POCT system which consists of a paper-based microarray chip,a homemade LEGO dark-box,and a smartphone installed with custom-designed FChip-APP,for on-site quantitation of Fe^(3+),Vitamin 12(VB12),and folic acid(FA).Collection and automatic analysis of fluorescence turn-off response of three kinds of fluorescent nanoprobes which are coated onto filter papers by a smartphone-based device is the principle behind this study.The POCT system exhibits good analytical performance for multiplexed analysis of Fe^(3+),VB_(12)and FA with a wide linear range(Fe^(3+),1.0–14.0μg mL^(-1)(R^(2)=0.983);VB_(12),1.35–40.0μg mL^(-1)(R^(2)=0.991);FA,2.0–26.0μg mL^(-1)(R^(2)=0.994))and low detection limit(Fe^(3+),0.35μg mL^(-1);VB12,0.47μg mL^(-1);FA,0.56μg mL^(-1)).The cost and weight of the whole system are~$220 and~600 g per set,highlighting its cost-eff ectiveness and portability.The simple operation procedures and user-friendly interface of the FChip-APP validate the ease-of-use feature of the reported system.This versatile smartphonebased quantitative POCT system provides a cost-eff ective and easy-of-use method for screening the context-specific causes of anemia and thus its eff ective interventions in the future,especially in resource-limited areas.